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Abstract 1 
Objectives: The aim of the study was to identify any unexpected clinical events associated 2 
with starting the new CFC-free formulation of Atrovent® MDI in general practice in England.  3 
 4 
Methods: An active surveillance cohort study was conducted with a focus on selected clinical 5 
events, including respiratory symptoms, in past users of Atrovent® CFC MDI (‘switchers’) 6 
and Atrovent® naïve users. Incidence density rate ratios (with 99% confidence intervals) for 7 
events occurring in the first three months of exposure (risk period-ID1-3) compared to three 8 
months prior to starting treatment (reference period-IDR) were calculated.  9 
 10 
Results: The cohort consisted of 13,211 patients (median age 70 years, 50.1% female; 63.5% 11 
prior users of Atrovent® CFC MDI (‘switchers’)). Common respiratory events occurred at 12 
higher rates after starting treatment than before for switchers e.g Lower respiratory tract 13 
infection (LRTI) [ID1/IDR=1.45 (99%CI: 1.17, 1.81)] and worsening asthma [ID1/IDR= 1.58 14 
(99%CI: 1.00, 2.51)]. Of these events only LRTI was significant for Atrovent® naïve patients 15 
[ID1/IDR= 1.42 (99%CI: 1.04, 1.95)].  16 
 17 
Conclusions: The results of this study suggest effect modification of risk as a result of prior 18 
Atrovent® CFC MDI use. Overall, Atrovent® CFC-free MDI appeared to be reasonably well 19 
tolerated in the immediate post-marketing period and the safety profile appeared similar to 20 
that of the CFC formulation.   21 
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1. Introduction 1 
Atrovent® chlorofluorocarbon (CFC)-Free metered dose inhaler (MDI) is a CFC-free 2 
formulation of the short-acting anticholinergic bronchodilator, ipratropium bromide. 3 
Ipratropium bromide is indicated for “the regular treatment of reversible bronchospasm 4 
associated with chronic obstructive pulmonary disease (COPD) and chronic asthma”.1 The 5 
CFC-free formulation of Atrovent® MDI was introduced after a decision to phase out CFC 6 
propellants due to environmental concerns over the ozone layer.2 Hydrofluoroalkane 1,1,1,2-7 
Tetrafluoroethane (HFA 134a) is an alternative propellant for metered dose inhalers (MDI) 8 
that has been developed and is used in the CFC-free formulation of Atrovent® MDI.2   9 
 10 
An active surveillance cohort study was requested by regulators of the manufacturer with an 11 
overall aim to monitor the introduction of the CFC-free formulation in general practice in 12 
England, following the switch from the CFC containing formulation of Atrovent® MDI. The 13 
primary objective of the study was to identify any unexpected clinical events associated with 14 
starting the CFC-free formulation of Atrovent® MDI, including paradoxical bronchospasm. 15 
The secondary objective of the study was to monitor the safety of patients previously and 16 
newly exposed (Atrovent® naïve) to Atrovent® CFC-free MDI in the immediate post 17 
marketing period. Of particular interest for both the primary and secondary objectives were 18 
respiratory events reported within the first three months after starting treatment, compared to 19 
the three months prior to starting treatment. 20 
 21 
To complement the information regarding safety collected from clinical studies and 22 
spontaneous reporting schemes, the Drug Safety Research Unit (DSRU) carries out post-23 
marketing surveillance studies of newly marketed drugs with widespread use in primary care 24 
in England, using the observational cohort technique known as Modified Prescription-Event 25 
  
4 
Monitoring (M-PEM), which retains all the strengths of the standard observational cohort 1 
technique of Prescription-Event Monitoring (PEM)3, but offers more targeted safety 2 
surveillance through use of bespoke questionnaires. Such a design was used for this study to 3 
monitor the introduction of Atrovent® CFC-free inhaler. The main aim of the study was to 4 
identify any unexpected clinical events associated with starting the new CFC-free formulation 5 
of Atrovent® MDI in general practice in England. 6 
 7 
2. Methods 8 
An M-PEM study was conducted to monitor the safety of Atrovent® CFC-free MDI as used in 9 
general practice in England. The methods of M-PEM are reported elsewhere.5 Briefly, patients 10 
were identified by means of data from dispensed National Health Service (NHS) 11 
prescriptions, written by General Practitioners (GPs) in England between May 2004 and 12 
February 2005.  These prescription data were supplied in confidence to the DSRU by the 13 
NHS Business Services Authority (NHSBSA).  14 
  15 
At least three months after the first identified prescription was issued for each patient, the 16 
prescribing doctor was sent a questionnaire by post. GPs were asked to select the prescribing 17 
indication from a list provided on the questionnaire.  Where two indications were selected, 18 
these were both recorded as the prescribing indication e.g. COPD/Asthma. GPs were also 19 
asked questions about when treatment was started and stopped (if applicable), relevant past 20 
medical history and any events experienced by the patient in the three months prior to 21 
treatment, during treatment and/or in the 30 days after stopping. All indications, relevant past 22 
medical history and events reported on questionnaires were coded onto a DSRU database 23 
using a hierarchical event dictionary arranged in a system-organ classification, containing 24 
higher, lower and doctor summary level terms. 25 
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 1 
2.1 Ethics  2 
 3 
This study was conducted in accordance with national and international guidelines6-8. In 4 
addition, under Section 251 of the NHS Act 2006, the DSRU have received support from the 5 
Ethics and Confidentiality Committee of the National Information Governance Board to gain 6 
access to and process patient identifiable information without consent for the purposes of 7 
medical research (October 2009). 8 
 9 
2.2 Sample size calculation 10 
 11 
To find statistically significant differences between number of events occurring prior to and 12 
after the first prescription for Atrovent® CFC-Free MDI, for events occurring during the pre-13 
exposure period at a frequency of 1/1000 patients and in the post-exposure period at 3/1,000 14 
patients with a power of at least 80%, for a confidence of 99% we needed to recruit at least 15 
12,634 users of Atrovent® CFC-Free MDI (EpiInfo V3.5.1, Atlanta, Georgia).  16 
 17 
2.3 Data analysis 18 
Summary statistics were produced for patient characteristics (including past medical history), 19 
prescribing information and medical event data at aggregate level. Crude odds ratios were 20 
calculated for cohort and drug utilisation characteristics comparing naïve users to switchers 21 
using STATA v12 (College Station, TX: StataCorp LP). Incidence density rates were 22 
calculated for all events reported during treatment for the overall three month post-treatment 23 
period (ID1-3). The figures are expressed as ID per 1000 patient-months of treatment. Within this 24 
period, two risk periods were defined according to: treatment in the first month after starting 25 
Atrovent® CFC-Free MDI (ID1) (“high risk period”), and for the second and third months 26 
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combined (ID2-3) (“low risk period”) (Figure 1). For individuals who discontinued treatment 1 
during the high risk period, a nominal risk period was used equal to the average high risk 2 
period observed in the study. If any individual died, a nominal observation period was used 3 
based on the average time from event to discharge in other cases.   4 
 5 
IDs were also calculated for the three month period prior to starting Atrovent® CFC-Free 6 
MDI- the “reference period” (IDR). Incidence density rate ratios were calculated (99% 7 
confidence intervals [CI]) for events, comparing incidence density rates in the high and low 8 
risk periods to the reference period. This examined the null hypothesis that the rate for the 9 
event was not increasing or decreasing between the two time periods.9 The first report of an 10 
event for the prior (reference period) and post (3-months after starting treatment) period was 11 
included for the incidence density rate ratios, which was an unmatched analysis.  12 
 13 
As IDs for the overall cohort may sometimes mask significant signals in specific risk groups 14 
(Atrovent® naïve, switchers, asthma patients and COPD patients [not mutually exclusive]), 15 
these subgroups had IDs calculated and compared according to strata for respiratory events 16 
(ID1/IDR, ID2-3/IDR and ID1-3/IDR for lower respiratory tract infection, dyspnoea and asthma 17 
worse). To minimise confounding, a matched pair analysis was conducted which calculated 18 
the risk ratio in the three month observation period pre and post starting Atrovent® CFC-Free 19 
MDI for a priori selected respiratory events at lower level term. Risk ratios (99% CI) were 20 
calculated to compare the frequency of selected events in the ‘before’ and ‘after’ periods. Use 21 
of a matched analysis improved the power of the statistical test from the unmatched analysis 22 
because of the controlling of the matched covariates.  23 
 24 
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3. Results 1 
3.1 Cohort accrual data and characteristics 2 
 3 
Dispensed prescriptions were written by 12,771 GPs. Of the 25,706 questionnaires posted to 4 
the prescribing GPs, 51.4% (13,211) questionnaires returned contained valid information 5 
(16,186 questionnaires returned in total; 63%). The final study cohort comprised 13,211 6 
patients (median age 70 years; 50.1% female). Cohort characteristics are presented in Table 1. 7 
The majority of patients in the cohort were switchers from Atrovent® CFC inhaler (8,390, 8 
63.5% of cohort) (Table 1).  9 
 10 
The most frequently reported indication for prescribing Atrovent® CFC-Free MDI was COPD 11 
(n=8,408, 63.6% of cohort; 64.4% where indication specified and only in adults), followed by 12 
Asthma (n=3161, 23.9% of cohort; 24.2% where indication specified). Further information on 13 
the drug utilisation characteristics of the cohort is provided in Table 2. 14 
 15 
The season when Atrovent® CFC-free inhaler was started was of interest as the winter season 16 
is associated with an increased incidence of influenza and respiratory tract infections10-12, 17 
which may result in an increased number of events during this period or may be related to the 18 
indication for treatment. The majority of patients (59.6% of cohort) started treatment with 19 
Atrovent® CFC-free in the autumn and winter months.   20 
 21 
3.2 Respiratory events and incidence density ratios for whole cohort 22 
 23 
  
8 
The respiratory system organ class had the most events reported overall (4,617, 33.3% of 1 
events reported), with the majority of these events occurring post treatment (2,455, 53.2% of 2 
respiratory events reported). There were no reports of paradoxical bronchospasm in the study. 3 
 4 
The event with the highest incidence density rate (ID) in the first month of treatment was 5 
‘Lower respiratory tract infection’ (ID1=25.25). The incidence density rate for the total risk 6 
period compared to the reference period (ID1-3/IDR) revealed significantly increased rates for 7 
‘Lower respiratory tract infection’ (ID1-3/IDR= 1.28, 99% CI: 1.12,1.46) and ‘COPD’ (ID1-8 
3/IDR= 1.29, 99% CI: 1.10,1.51) in the total risk period.  The corresponding ID ratios for the 9 
first month of treatment compared to the reference period (ID1/IDR), revealed a significantly 10 
increased rate for ‘Lower respiratory tract infection’ in the first month of treatment (‘high risk 11 
period’) compared to the reference period (ID1/IDR= 1.42, 99% CI: 1.19,1.69), and also in the 12 
‘low risk period’ compared to the reference period (ID2-3/IDR= 1.20, 99% CI: 1.03, 1.40), 13 
although the point estimate was slightly lower.  The rate was also significantly increased in 14 
the first month of treatment for ‘COPD’ compared to the reference period (ID1/IDR= 1.52, 15 
99% CI: 1.24,1.86), but there was no significant difference observed for the low risk period 16 
(ID2-3/IDR= 1.17, 99% CI: 0.97- 1.40). Of note, the dictionary higher level term ‘COPD’ 17 
encompasses exacerbations of the disease as well as new diagnoses.  18 
 19 
3.3 Stratified incidence density rate ratios for Atrovent® naïve patients and switchers 20 
from Atrovent® CFC MDI 21 
 22 
Clinical event rates significantly associated with the high risk period in Atrovent® naive 23 
patients compared to the reference period included ‘Lower respiratory tract infection’(Figure 24 
2) and ‘Respiratory tests’ (ID1/IDR= 4.35, 99%CI: 1.28, 14.74).   25 
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 1 
In the Atrovent® CFC MDI switchers subset, an event rate significantly associated with the 2 
high risk period compared to the reference period was for the event ‘Lower respiratory tract 3 
infection’ (Figure 2). However, unlike the naive subset, this event had a rate which was also 4 
significantly higher in the low risk period compared to the reference period.  In addition, the 5 
rate of ‘COPD’ was significantly associated with both the high and low risk period (ID1/IDR= 6 
1.66, 99%CI: 1.31, 2.11; ID2-3/IDR= 1.26, 99%CI: 1.02, 1.56).   7 
 8 
In  Atrovent® CFC MDI switchers, the rate of ’Asthma worse’ was associated with starting 9 
treatment in the high risk period compared to the reference period, although of borderline 10 
significance.  The rate of ‘dyspnoea’ was not significantly increased or decreased during the 11 
high risk, low risk or total risk periods for both Atrovent® naïve and switcher patients.  12 
 13 
3.4 Matched analysis results 14 
 15 
For all patients in the matched analysis, risk of hospital admissions (RR=1.35, 99% CI: 1.11, 16 
1.65) was significantly greater in the 3 month period after starting than before (Table 3). Also, 17 
patients were at greater risk of taking high dose oral steroids (RR=1.21, 99% CI: 1.11-1.32) in 18 
the three months post treatment, compared to the three months prior to treatment.   19 
 20 
After stratification by prior use of Atrovent® CFC MDI, naive users showed a decrease in the 21 
risk of dyspnoea after starting treatment with Atrovent® CFC-free, compared to the reference 22 
period. Atrovent® naïve patients had a significantly increased risk of respiratory hospital 23 
referrals after starting treatment compared to the reference period. In contrast to Atrovent® 24 
naive patients, for Atrovent® switcher patients, dyspnoea was not shown to be significantly 25 
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associated with the risk period or the reference period. However, for switchers there was an 1 
observation of more frequent use of high dose steroids after starting treatment than prior to 2 
starting treatment. 3 
 4 
3.5 Stratified incidence density rate ratios for COPD and Asthma patients 5 
 6 
To determine if the indication for treatment had an effect on the incidence density rate ratios, 7 
these were further stratified into COPD and asthma patients (Figure 2). 8 
 9 
After stratification by indication, the trend for an increased rate of LRTI after starting 10 
treatment was only significantly increased in COPD patients in months 1 and 1-3 of treatment 11 
(Figure 2). No other incidence density rates were significantly increased or decreased in 12 
COPD and asthma patients.  13 
 14 
4. Discussion 15 
4.1 Main study findings 16 
 17 
Elevated rates of respiratory events in the period after starting treatment in switcher and 18 
COPD patients was observed, along with decreased rates of dyspnoea in the period after 19 
starting treatment in naïve patients. Since the main aim of the study was to identify any 20 
unexpected clinical events associated with starting the new CFC-free formulation of 21 
Atrovent® MDI in general practice in England, these results clearly address this aim. Overall, 22 
the before and after study design for examining events was successful for estimating the effect 23 
of introducing the CFC-free inhaler into England.  24 
 25 
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4.2 Strengths and limitations 1 
 2 
One of the major strengths of PEM methodology is that it is non interventional and does not 3 
influence the prescribing practices of GP’s. There are also no exclusion criteria i.e. all patients 4 
prescribed and dispensed the study drug are eligible for inclusion.  5 
 6 
However, of the questionnaires sent to GPs (25706), 16186 (63%) were returned.  This study 7 
did not assess the impact of non-response bias but this response rate is comparable to to 8 
response rates reported elsewhere for GP postal surveys 25 and higher than the reporting rates 9 
of suspected ADRs in the Yellow Card Scheme.26-27 Additionally, under reporting of adverse 10 
events, including serious and fatal events, is possible in PEM as not all events may be 11 
reported to the GP by the patient.  Also, as an observational study, it is not possible to 12 
estimate the amount of patient compliance with Atrovent® CFC-free MDI.   13 
 14 
The delay in submission of this paper was due to several factors: the time required to review 15 
questionnaires, code data, perform data cleaning and analysis. There was also a requirement 16 
to perform further data analysis, stratifying by indication. However, we feel this paper is still 17 
useful for pharmacy practice and that it is important to communicate our findings regarding 18 
respiratory events in this patient population. The results still contribute additional information 19 
to the current knowledge about this medication. 20 
 21 
4.3 Event profiles 22 
The majority of patients in the cohort were switchers from Atrovent® CFC MDI (8,390, 23 
63.5%). It was observed that switchers from Atrovent® CFC MDI were more likely to be 24 
adults, have an indication of COPD and have moderate/severe disease.  Due to the 25 
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pathological differences between asthma and COPD alone, patients would experience 1 
different events13-14, but additionally age and disease severity can also create different event 2 
profiles15-17.  3 
 4 
The high risk period was associated with increased reports of both asthma worse and COPD 5 
in switchers. The same observation for COPD was also observed for the entire cohort. 6 
‘COPD’ is an indication related higher and lower level term which incorporates the doctor 7 
summary terms ‘COPD exacerbation’ and ‘COPD uncontrolled’, among other terms.  Since 8 
COPD is a progressive disease which can only be controlled and not improved18, it would be 9 
expected for patients to experience these events whilst using Atrovent® CFC-free inhaler. 10 
‘Asthma worse’ is an indication related event that indicates a patient’s asthma is not being 11 
controlled and is worsening. This indicates that a patient will need to ‘step up’ their therapy19 12 
or change their therapy in an attempt to control their symptoms.  Unlike COPD patients, 13 
asthma is a disease which can be improved with the right combination of therapy13,19.  An 14 
explanation for the association with the high risk period for switchers from Atrovent® CFC 15 
MDI is the seasonality of respiratory tract infections resulting in increased acute 16 
exacerbations, and the fact that many patients started Atrovent® CFC-free inhaler in the 17 
winter months.10-12   18 
 19 
For both subsets of patients, the frequency of lower respiratory tract infection was higher after 20 
starting treatment than prior. This may be due to calendar time of starting treatment 21 
(seasonality) since the majority of patients (59.6%) started treatment with Atrovent® CFC-free 22 
MDI in the autumn and winter months. The winter season is associated with an increased 23 
incidence of influenza and respiratory tract infections10-12, 20, which could provide one 24 
explanation of the results of this unmatched analysis. This effect has been seen in another 25 
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PEM study conducted on the introduction of the CFC-free formulation of Ventolin® Evohaler 1 
into the UK population.21 Another explanation is protopathic bias.  This occurs when the 2 
pharmacological agent is prescribed for early manifestation of a condition that has not yet 3 
been diagnosed, but which then appears to be the cause of the condition when it is eventually 4 
diagnosed.22  Thus, our hypothesis is that both subgroups of patients sought medical advice 5 
because of worsening respiratory function, which later turned out to be associated with lower 6 
respiratory tract infection, and this diagnosis was recorded at the same time as starting the 7 
new CFC-free version of Atrovent®.  8 
 9 
The results of the matched analysis support the observations regarding differences in the event 10 
profile between  switchers from Atrovent® CFC MDI compared to those who are Atrovent® 11 
naive, particularly in terms of severity of indication, ongoing monitoring/referrals and 12 
admissions to hospital. The matched analysis produced significant risk ratios for use of high 13 
dose oral steroids and hospital admissions for the whole cohort.  The significant risk ratio for 14 
high dose oral steroids may have been confounded by the increased rate of concomitant lower 15 
respiratory tract infections, since patients may require oral steroids to control their disease 16 
whilst fighting the infection23. Due to the elderly population in the cohort, and the high 17 
number of patients with COPD, hospital admissions are not unexpected as patients may have 18 
experienced exacerbations of COPD requiring admission24, or any other condition relating to 19 
age which required admission.  Additionally, the high number of admissions may have been 20 
related to the season most patients started Atrovent® CFC-free (winter), which is associated 21 
with increased hospitalisation due to respiratory infections.10-12, 20    Stratified risk estimates of 22 
respiratory events such as dyspnoea and respiratory hospital referrals indicate effect 23 
modification by past use of Atrovent® CFC MDI.  This provides further evidence that when 24 
  
14 
undertaking surveillance studies, it is important to present and discuss issues concerning 1 
safety and use separately in these sub-sets.  2 
 3 
The observation of elevated rates of respiratory events in the period after starting treatment in 4 
switcher and COPD patients could be suggestive of a period of increased risk after changing 5 
treatment regimen in these patients. However, an alternative explanation could be that COPD 6 
patients are more likely to experience dyspnoea which cannot improve over time, due to the 7 
nature of the disease. In contrast, the cause of dyspnoea in asthma patients can be treated and 8 
so improve over time.  9 
 10 
The observation of decreased rates of dyspnoea in the period after starting treatment in naïve 11 
patients could be suggestive of a protective effect of Atrovent CFC-free inhaler. A possible 12 
explanation for this is that patient’s respiratory disease was uncontrolled prior to starting the 13 
inhaler, resulting in a higher event rate compared to after starting treatment. 14 
 15 
5 Conclusion 16 
 17 
The results of this study suggest possible effect modification of risk as a result of prior 18 
Atrovent® CFC MDI use and this should be taken into consideration when evaluating the risk 19 
benefit profile of new CFC-free formulation inhalers. Overall, Atrovent® CFC-free MDI 20 
appeared to be reasonably well tolerated in the immediate post-marketing period and the 21 
safety profile appeared to be similar to that of the CFC formulation MDI.   22 
 23 
 24 
 25 
26 
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Table 1. Cohort characteristics according to prior use of Atrovent® CFC MDI 1 
 2 
 3 
 
Atrovent CFC-free MDI use status 
 
Switcher 
(n=8390) 
Naïve user 
(n=3780) 
TOTAL 
(N=12170) *Not 
Known =1041 
Odds ratio* (95% 
CI) 
Gender        
Male 4106 (67.5%) 1974 (32.5%) 6080 
1.14 (1.06, 1.23) 
Female1 4278 (70.3%) 1804 (29.7%) 6082 
Not Known 6 2 8  
Age     
 <=5 yrs 132 (18.4%) 587 (81.6%) 719 11.59 (9.55, 14.06) 
6-12 yrs 32 (46.4%) 37 (53.6%) 69 3.01 (1.87, 4.85) 
13+ yrs1 8226 (72.3%) 3156 (27.7%) 11382 1.00 
Not Known 0 0 0  
Oral steroid use 
either before or 
during treatment 
    
Yes 1422 (68.6%) 651 (31.4%) 2073 
1.01 (0.91, 1.12) 
No1 6722 (68.85) 3041 (31.2) 9763 
Not known  246 88 334  
Smoking status2     
Current or 
previous smoker 
6467 (72.5%) 2449 (27.5%) 8916 
0.76 (0.69, 0.84) 
Non smoker1 1422 (70.9%) 585 (29.2%) 2007 
Not known  337 122 459  
Hospitalised 3 
months prior to 
starting 
    
Yes 935 (68.5%) 430 (31.5%) 1365 
1.02 (0.90, 1.15) 
No1 7140 (68.9%) 3224 (31.1%) 10364 
Not known  315 126 441  
*Odds ratio of switchers compared to naïve users 4 
1Chracteristics highlighted in bold were used as the baseline for comparison of the odds  5 
2Patients aged 13 years and over only 6 
Switchers are defined as prior users of Atrovent CFC containing MDI, while naïve users have no previous use of 7 
Atrovent CFC containing MDI 8 
9 
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Table 2. Drug utilisation according to prior use of Atrovent® CFC MDI 1 
 2 
 
Atrovent CFC-free MDI use status 
 
Switcher (n=8390) naïve user) 
TOTAL 
(N=12170) *Not 
Known =1041 
Odds ratio* 
(95% CI) 
Total puffs at start        
1-3 380 (50.5%) 373 (49.5%) 753 2.50 (2.14, 2.92) 
4-7 3197 (66.9%) 1582 (33.1%) 4779 1.26 (1.16, 1.37) 
81 3737 (71.8%) 1465 (28.2%) 5202 1.00 
9+ 423 (86.9%) 64 (13.1%) 487 0.39 (0.29, 0.51) 
Not Known 653 296 949  
Indication     
COPD1 5733 (73.2%) 2097 (26.8%) 7830 1.00 
Asthma 1875 (65.0%) 1011 (35.0%) 2886 1.47 (1.35, 1.62) 
COPD/Asthma 473 (78.2%) 132 (21.8%) 605 0.76 (0.63, 0.93) 
COPD/Other 70 (69.3%) 31 (30.7%) 101 1.21 (0.79, 1.85) 
Asthma/Other 48 (23.2%) 159 (76.8%) 207 9.06 (6.53, 12.55) 
Other 148 (32.5%) 307 (67.5%) 455 5.67 (4.63, 6.94) 
Not Known 43 43 86  
GP opinion on 
severity of disease 
    
Mild1 1348 (56.9%) 1023 (43.2%) 2371 1.00 
Moderate 4584 (70.4%) 1930 (29.6%) 6514 0.55 (0.50, 0.61) 
Severe 2021 (77.6%) 582 (22.4%) 2603 0.38 (0.34, 0.43) 
Not Known 437 245 682  
*Odds ratio of switchers compared to naïve users 3 
1Chracteristics highlighted in bold were used as the baseline for comparison of the odds  4 
Switchers are defined as prior users of Atrovent CFC containing MDI, while naïve users have no previous use of 5 
Atrovent CFC containing MDI6 
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Table 3. Matched analysis results for selected events in naïve and switcher patients 1 
 2 
 Naïve Switcher 
Event type Risk Ratio 99% CI p-value Risk Ratio 99% CI p-value 
  Lower Upper   Lower Upper  
Asthma worse 0.95 0.58 1.55 0.776 1.29 0.90 1.83 0.066 
Hospital referrals: Respiratory 4.20 1.17 15.13 0.004 1.41 0.69 2.89 0.219 
Hospital admissions 1.02 0.71 1.46 0.889 1.68 1.26 2.24 < .001 
Dyspnoea 0.60 0.36 1.00 0.010 1.36 0.93 1.98 0.037 
High dose oral steroids 1.09 0.90 1.32 0.309 1.28 1.13 1.46 < .001 
Switchers are defined as prior users of Atrovent CFC containing MDI, while naïve users have no previous use of 3 
Atrovent CFC containing MDI 4 
 5 
 6 
 7 
 8 
Figure 1. Treatment periods used in incidence density rate analysis  9 
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Figure 2. Plot of rate ratios and 99% confidence intervals for respiratory events, 1 
stratified by prior Atrovent CFC MDI use and indication  2 
 3 
  LRTI= Lower Respiratory Tract Infection  4 
  5 
 6 
